These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 17100638)

  • 21. Allosteric inhibition of the hepatitis C virus NS5B polymerase: in silico strategies for drug discovery and development.
    Barreca ML; Iraci N; Manfroni G; Cecchetti V
    Future Med Chem; 2011 Jun; 3(8):1027-55. PubMed ID: 21707403
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Update on different aspects of HCV variability: focus on NS5B polymerase.
    Marascio N; Torti C; Liberto M; Focà A
    BMC Infect Dis; 2014; 14 Suppl 5(Suppl 5):S1. PubMed ID: 25234810
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hepatitis C Viral Replication Complex.
    Li HC; Yang CH; Lo SY
    Viruses; 2021 Mar; 13(3):. PubMed ID: 33809897
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synthesis and anti-HCV activity of 3',4'-oxetane nucleosides.
    Chang W; Du J; Rachakonda S; Ross BS; Convers-Reignier S; Yau WT; Pons JF; Murakami E; Bao H; Steuer HM; Furman PA; Otto MJ; Sofia MJ
    Bioorg Med Chem Lett; 2010 Aug; 20(15):4539-43. PubMed ID: 20580554
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Robust antiviral efficacy upon administration of a nucleoside analog to hepatitis C virus-infected chimpanzees.
    Carroll SS; Ludmerer S; Handt L; Koeplinger K; Zhang NR; Graham D; Davies ME; MacCoss M; Hazuda D; Olsen DB
    Antimicrob Agents Chemother; 2009 Mar; 53(3):926-34. PubMed ID: 19075052
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hepatitis C replication inhibitors that target the viral NS4B protein.
    Miller JF; Chong PY; Shotwell JB; Catalano JG; Tai VW; Fang J; Banka AL; Roberts CD; Youngman M; Zhang H; Xiong Z; Mathis A; Pouliot JJ; Hamatake RK; Price DJ; Seal JW; Stroup LL; Creech KL; Carballo LH; Todd D; Spaltenstein A; Furst S; Hong Z; Peat AJ
    J Med Chem; 2014 Mar; 57(5):2107-20. PubMed ID: 23544424
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antiviral activity and resistance of HCV NS5A replication complex inhibitors.
    Gao M
    Curr Opin Virol; 2013 Oct; 3(5):514-20. PubMed ID: 23896281
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect.
    Gao M; Nettles RE; Belema M; Snyder LB; Nguyen VN; Fridell RA; Serrano-Wu MH; Langley DR; Sun JH; O'Boyle DR; Lemm JA; Wang C; Knipe JO; Chien C; Colonno RJ; Grasela DM; Meanwell NA; Hamann LG
    Nature; 2010 May; 465(7294):96-100. PubMed ID: 20410884
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Resistance analysis and characterization of NITD008 as an adenosine analog inhibitor against hepatitis C virus.
    Qing J; Luo R; Wang Y; Nong J; Wu M; Shao Y; Tang R; Yu X; Yin Z; Sun Y
    Antiviral Res; 2016 Feb; 126():43-54. PubMed ID: 26724382
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combinations of cyclophilin inhibitor NIM811 with hepatitis C Virus NS3-4A Protease or NS5B polymerase inhibitors enhance antiviral activity and suppress the emergence of resistance.
    Mathy JE; Ma S; Compton T; Lin K
    Antimicrob Agents Chemother; 2008 Sep; 52(9):3267-75. PubMed ID: 18591281
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Discovery of a novel series of potent non-nucleoside inhibitors of hepatitis C virus NS5B.
    Schoenfeld RC; Bourdet DL; Brameld KA; Chin E; de Vicente J; Fung A; Harris SF; Lee EK; Le Pogam S; Leveque V; Li J; Lui AS; Najera I; Rajyaguru S; Sangi M; Steiner S; Talamas FX; Taygerly JP; Zhao J
    J Med Chem; 2013 Oct; 56(20):8163-82. PubMed ID: 24069953
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synthesis of potent and broad genotypically active NS5B HCV non-nucleoside inhibitors binding to the thumb domain allosteric site 2 of the viral polymerase.
    Pierra Rouvière C; Amador A; Badaroux E; Convard T; Da Costa D; Dukhan D; Griffe L; Griffon JF; LaColla M; Leroy F; Liuzzi M; Loi AG; McCarville J; Mascia V; Milhau J; Onidi L; Paparin JL; Rahali R; Sais E; Seifer M; Surleraux D; Standring D; Dousson C
    Bioorg Med Chem Lett; 2016 Sep; 26(18):4536-4541. PubMed ID: 27520942
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nucleoside analog inhibitors of hepatitis C viral replication: recent advances, challenges and trends.
    Furman PA; Lam AM; Murakami E
    Future Med Chem; 2009 Nov; 1(8):1429-52. PubMed ID: 21426058
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Discovery of fused tricyclic core containing HCV NS5A inhibitors with pan-genotype activity.
    Yu W; Coburn CA; Yang DY; Meinke PT; Wong M; Rosenblum SB; Chen KX; Njoroge GF; Chen L; Dwyer MP; Jiang Y; Nair AG; Selyutin O; Tong L; Zeng Q; Zhong B; Ji T; Hu B; Agrawal S; Xia E; Zhai Y; Liu R; Kong R; Ingravallo P; Asante-Appiah E; Nomeir A; Fells J; Kozlowski JA
    Bioorg Med Chem Lett; 2016 Jul; 26(13):3158-3162. PubMed ID: 27180013
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The therapeutic potential of NS3 protease inhibitors in HCV infection.
    Goudreau N; Llinàs-Brunet M
    Expert Opin Investig Drugs; 2005 Sep; 14(9):1129-44. PubMed ID: 16144497
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recent advances in drug discovery of benzothiadiazine and related analogs as HCV NS5B polymerase inhibitors.
    Das D; Hong J; Chen SH; Wang G; Beigelman L; Seiwert SD; Buckman BO
    Bioorg Med Chem; 2011 Aug; 19(16):4690-703. PubMed ID: 21798747
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of hepatitis C virus replication by GS-6620, a potent C-nucleoside monophosphate prodrug.
    Feng JY; Cheng G; Perry J; Barauskas O; Xu Y; Fenaux M; Eng S; Tirunagari N; Peng B; Yu M; Tian Y; Lee YJ; Stepan G; Lagpacan LL; Jin D; Hung M; Ku KS; Han B; Kitrinos K; Perron M; Birkus G; Wong KA; Zhong W; Kim CU; Carey A; Cho A; Ray AS
    Antimicrob Agents Chemother; 2014; 58(4):1930-42. PubMed ID: 24419349
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discovery of the first C-nucleoside HCV polymerase inhibitor (GS-6620) with demonstrated antiviral response in HCV infected patients.
    Cho A; Zhang L; Xu J; Lee R; Butler T; Metobo S; Aktoudianakis V; Lew W; Ye H; Clarke M; Doerffler E; Byun D; Wang T; Babusis D; Carey AC; German P; Sauer D; Zhong W; Rossi S; Fenaux M; McHutchison JG; Perry J; Feng J; Ray AS; Kim CU
    J Med Chem; 2014 Mar; 57(5):1812-25. PubMed ID: 23547794
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Allosteric inhibition of the hepatitis C virus NS5B RNA dependent RNA polymerase.
    Koch U; Narjes F
    Infect Disord Drug Targets; 2006 Mar; 6(1):31-41. PubMed ID: 16787302
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Synthesis and antiviral properties of novel 7-heterocyclic substituted 7-deaza-adenine nucleoside inhibitors of Hepatitis C NS5B polymerase.
    Di Francesco ME; Avolio S; Pompei M; Pesci S; Monteagudo E; Pucci V; Giuliano C; Fiore F; Rowley M; Summa V
    Bioorg Med Chem; 2012 Aug; 20(15):4801-11. PubMed ID: 22770556
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.